Recent Updates — IMAB
NovaBridge Biosciences announced the appointment of Charles "Chuck" Silberstein, M.D., M.B.A., CFA, as Chief Financial Officer, effective November 2, 2026. Dr. Silberstein succeeds Ming (Kyler) Lei, who tendered his resignation as CFO effective October 30, 2026. The company stated that Mr. Lei's departure was not due to any disagreement regarding operations or policies. Dr. Silberstein brings over 25 years of experience in biotechnology leadership and capital markets, previously serving as CEO of FytonBio and CFO at GentiBio and Applied Therapeutics. He joins the company as it advances its lead clinical programs and pursues strategic partnerships. NovaBridge Biosciences is a global biotechnology company focused on identifying, developing, and maximizing the value of differentiated therapeutic assets through clinical development and strategic partnering.
NovaBridge Biosciences announced updated results from its ongoing Phase 1b study of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, presented at the ESMO Congress 2026. The dataset includes nearly 18 months of median follow-up for 71 patients and supports the selection of the 8 mg/kg dose for registrational development in first-line metastatic gastroesophageal adenocarcinoma. Among efficacy-evaluable patients at this dose, the objective response rate was 79%, with a median duration of response of 15.2 months and median progression-free survival of 16.9 months. Clinical activity was observed across CLDN18.2 expression levels, including an 82% response rate in patients with high expression (≥75%) and 75% in those with lower expression (1%-74%). The company highlighted alignment with the FDA on a global Phase 3 study protocol, alongside existing Orphan Drug and Fast Track Designations. NovaBridge is a biotechnology company advancing therapeutic programs in oncology and ophthalmology.
Clinical data from the ongoing Phase 1 clinical trial of ragistomig (ABL503/TJ-L14B), a bispecific antibody targeting PD-L1 and 4-1BB, were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026. The data was presented by ABL Bio Inc., with whom NovaBridge Biosciences is jointly developing the asset, on October 23, 2026, in Madrid, Spain. This disclosure provides preliminary clinical information regarding the company's lead candidate but does not constitute a regulatory approval or commercial milestone. NovaBridge Biosciences operates as a biotechnology company focused on the development of novel immunotherapies.
Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, entered into an exclusive license agreement with Wuhan Hiteck Biological Pharma Co., Ltd. on October 13, 2026, for the development and commercialization of VIS-102 (HT006.2.2) worldwide, excluding Greater China. Visara will pay Hiteck a $7.0 million upfront payment and is obligated to make additional aggregate milestone payments of up to $104.0 million based on clinical and commercial achievements. The agreement also includes tiered royalties on net sales. VIS-102 is an investigational modified recombinant human nerve growth factor therapy designed to treat neurotrophic keratitis, a rare degenerative eye disease. NovaBridge Biosciences operates as a global biotechnology company advancing therapeutic programs in oncology and ophthalmology.
NovaBridge Biosciences held its Annual General Meeting on September 8, 2026, with shareholders representing approximately 44.8% of outstanding shares present. The company removed Ms. Xin Liu from her position as a director with immediate effect following an ordinary resolution vote of 107,925,508 in favor and 13,313,327 against. This executive departure constitutes a material governance change affecting the company's leadership structure. NovaBridge Biosciences operates in the biotechnology industry, focusing on drug discovery and development.
NovaBridge Biosciences appointed Martin Dewhurst as an independent director and member of the Audit and Compensation Committees on September 8, 2026. Mr. Dewhurst brings over 30 years of healthcare leadership experience, including co-leading McKinsey’s Global Life Sciences Practice and serving on multiple biotechnology boards. His appointment follows the departure of independent director Liu Xin from the Board. NovaBridge Biosciences is a global biotechnology company advancing therapeutic programs in oncology and ophthalmology.